✦ LIBER ✦

Impact of pramipexole on the onset of levodopa-related dyskinesias

✍ Scribed by Radu Constantinescu; Megan Romer; Michael P. McDermott; Cornelia Kamp; Karl Kieburtz

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 63 KB
Volume: 22
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.21292

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Dyskinesias are a major complication of dopaminergic therapy in the long‐term treatment of Parkinson's disease. In the CALM‐PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Mechanisms underlying the onset and expr

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation

✍ Mahmoud M. Iravani; Peter Jenner 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 472 KB

Frequency of levodopa-related dyskinesia

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

✍ J. Eric Ahlskog; Manfred D. Muenter 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were

Levetiracetam for the management of levo

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease

✍ P. Stathis; S. Konitsiotis; G. Tagaris; D. Peterson; on Behalf of VALID-PD Study 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

The influence of levodopa-induced dyskin

The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson’s disease

✍ Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Roderick Edwards; Christian Duval 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 459 KB

Investigation of the impact of sarizotan

Investigation of the impact of sarizotan on the pharmacokinetics of levodopa

✍ Sonja Krösser; Roland Neugebauer; Didier Chassard; Andreas Kovar 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

Effect of histamine H2 receptor antagoni

Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP-macaque model of Parkinson's disease

✍ Tom H. Johnston; Anne van der Meij; Jonathan M. Brotchie; Susan H. Fox 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 823 KB

## Abstract Levodopa‐induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these probl